Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Aroa Biosurgery Ltd ( (AU:ARX) ).
Aroa Biosurgery Limited will host an investor webinar on 3 February, led by CEO Brian Ward and CFO James Agnew, to discuss a pre-market business update, including progress on Symphony™ and developments in US Medicare reimbursement, as well as newly published clinical data from the ongoing MASTRR study. The event signals the company’s efforts to deepen investor engagement and provide greater transparency around key growth drivers and clinical validation, with potential implications for its reimbursement outlook, product adoption and positioning in the US soft-tissue regeneration market.
The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Limited is a New Zealand-based soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products for complex wound healing and soft tissue reconstruction. Its products are built on the proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine forestomach, and have been used in more than 7 million procedures worldwide, with the United States as its key market served via a direct sales force and distribution partner TELA Bio, Inc.
Average Trading Volume: 251,059
Technical Sentiment Signal: Buy
Current Market Cap: A$248.4M
See more insights into ARX stock on TipRanks’ Stock Analysis page.